Table 5 Studies on the inhibitory effect of antibiotics on immunotherapy
From: The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Tumor type | Immunotherapy treatment | Number of included patients | Antibiotics | References |
|---|---|---|---|---|
Melanoma; NSCLC; blood cancer; renal cancer; etc. | αPD-1/PD-L1 mAb, αCTLA-4 mAb, or combination treatment | 635 | β-Lactam, sulfa, quinolones, macrolides aminoglycosides, tetracycline | [236] |
NSCLC; kidney cancer; bladder cancer; head and neck; melanoma | αPD-1/PD-L1 mAb, αCTLA-4 mAb, or combination treatment | 102 | β-Lactam; fluoroquinolone; cephalosporin; macrolides; sulfonamides | [237] |
NSCLC; melanoma; upper airway and digestive tract carcinoma; renal cell carcinoma | αPD-1 mAb | 212 | β-Lactam; fluoroquinolone; tetracycline class | [238] |
NSCLC | αPD-1 mAb; αPD-L1 mAb | 531 | β-Lactam | [239] |
NSCLC; RCC; melanoma; lung cancer; etc. | αPD-1/PD-L1 mAb, αCTLA-4 mAb, or combination treatment | 5565 | β-Lactam; quinolone; vancomycin; daptomycin; linezoldone; meropenem; azithromycin; furantoin; tetracycline; penicillin; etc. | [240] |
NSCLC; melanoma; etc. | αPD-1 mAb; αPD-L1 mAb | 196 | β-Lactam; quinolone; macrolides; sulfa; tetracycline; aminoglycosides; etc. | [241] |
NSCLC; melanoma; RCC; etc. | αPD-1/PD-L1 mAb, αCTLA-4 mAb, or combination treatment | 12,492 | β-Lactam; fluoroquinolone; penicillins; carbapenems; metronidazole; macrolides; linezolid; vancomycin; ciprofloxacin; meropenem; tetracyclines; levofloxacin | [242] |
Metastatic urothelial carcinoma (mUC) | αPD-1 mAb | 67 | Penicillins; cephalosporins; carbapenems; quinolone | [243] |
Muscle-invasive bladder cancer | αPD-1 mAb | 149 | Fluoroquinolones | [244] |
RCC | αPD-1 mAb | 93 | quinolone; amoxicillin | [245] |
Advanced melanoma | αCTLA-4 mAb | 1585 | Systemic antibiotic | [246] |
NSCLC; melanoma; RCC; others | αCTLA-4 mAb; αPD-L1 mAb; αPD-1 mAb | 217 | Concomitant systemic antibiotics | [247] |
Urothelial carcinoma | αPD-L1 mAb | 1360 | Penicillins; quinolone; cephalosporins; glycopeptide; carbapenems; sulfa; macrolides; aminoglycosides; etc. | [248] |
Acute myeloid leukemia (AML); NSCLC; RCC | ICI; chemotherapy | 338 | Piperacillin; clindamycin; metronidazole. meropenem; vancomycin; furantoin; rifampin. rifaximin; tobramycin | [249] |
RCC | αPD-1 mAb | 69 | β-Lactam; quinolone | [170] |
Melanoma | αPD-1 mAb; αCTLA-4 mAb; combined | 568 | Cephalosporins; penicillins; fluoroquinolone | [250] |
Bladder cancer; head and neck carcinoma; melanoma; NSCLC; RCC; sarcoma; others | αPD-1/PD-L1 mAb, αCTLA-4 mAb, or combination treatment | 690 | β-Lactam | [251] |
NSCLC; melanoma; urothelial carcinoma; RCC; lung cancer; sarcoma | αPD-1/PD-L1 mAb, αCTLA-4 mAb, or combination treatment | 2740 | Antibiotics | [252] |
NSCLC | αPD-1 mAb; | 234 | β-Lactam; cephalosporins; quinolone | [253] |
Melanoma | αPD-1 mAb; αCTLA-4 mAb; combined with chemotherapy | 74 | β-Lactam | [254] |
NSCLC | αPD-1 mAb; αCTLA-4 mAb | 109 | β-Lactam; fluoroquinolone; etc. | [255] |
NSCLC; RCC | Anti-PD-L1 | 360 | β-Lactam; quinolone; sulfa | [81] |
mRCC | αPD-1/PD-L1 mAb; mTOR inhibitors; IFN-α; VEGF-TT | 4290 | β-Lactam; fluoroquinolone; macrolides; tetracyclines; etc. | [256] |